CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
CORALVILLE, Iowa, April 05, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Needham & Company’s 15th Annual Healthcare Conference being held in New York, NY, April 12 - 13, 2016.
Details of KemPharm's presentation are as follows:
Date: Tuesday, April 12, 2016
Time: 10:40 AM (ET)
Location: Westin NY Grand Central Hotel; New York, NY
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
